Global EditionASIA 中文雙語(yǔ)Fran?ais
    World
    Home / World / Americas

    Johnson & Johnson pauses COVID-19 vaccine trial over patient illness

    Xinhua | Updated: 2020-10-13 14:04
    Share
    Share - WeChat

    WASHINGTON - US pharmaceutical company Johnson & Johnson said Monday it had paused its COVID-19 vaccine trial because one of its participants had become sick.

    "We have temporarily paused further dosing in all our COVID-19 vaccine candidate clinical trials, including the Phase 3 ENSEMBLE trial, due to an unexplained illness in a study participant," the company said in a statement.

    The patient's condition was being reviewed and evaluated by the ENSEMBLE independent Data Safety Monitoring Board as well as internal clinical and safety physicians, it said.

    There are prespecified guidelines for all clinical studies, said the company. "These ensure studies may be paused if an unexpected serious adverse event (SAE) that might be related to a vaccine or study drug is reported, so there can be a careful review of all of the medical information before deciding whether to restart the study."

    Johnson & Johnson said SAEs are not uncommon in clinical trials, and the number of SAEs can reasonably be expected to increase in trials involving large numbers of participants.

    As many trials are placebo-controlled, it is not always immediately apparent whether a participant received a study treatment or a placebo, according to the company.

    The phase 3 clinical trial of Johnson & Johnson's COVID-19 vaccine started on Sept 23. The trial is designed to evaluate if the vaccine candidate could prevent symptomatic COVID-19 after a single dose regimen.

    Up to 60,000 volunteers are scheduled to be enrolled in the trial at up to nearly 215 clinical research sites in the United States and internationally.

    It is the fourth large-scale phase 3 clinical trials for a COVID-19 vaccine in the United States. The other three trials are for vaccine candidate AZD1222, co-invented by the University of Oxford and its spin-out company Vaccitech; vaccine candidate mRNA-1273, developed by the US National Institute of Allergy and Infectious Diseases and American biotechnology company Moderna; and vaccine candidate BNT162b2, developed by American biopharmaceutical company Pfizer and German company BioNTech.

    Johnson & Johnson's vaccine wing Janssen is responsible for developing the shot. While the other vaccine candidates require two doses, the Janssen vaccine candidate will be studied as a single-dose vaccine. It is a recombinant vector vaccine that uses a human adenovirus to express the SARS-CoV-2 spike protein in cells.

    Most Viewed in 24 Hours
    Top
    BACK TO THE TOP
    English
    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
    亚洲AV日韩AV永久无码久久 | 无码中文字幕av免费放dvd| 日韩精品无码永久免费网站| 亚洲人成网亚洲欧洲无码久久| 亚洲日韩在线中文字幕第一页| 中文字幕免费在线| 日韩免费码中文在线观看 | 无码 免费 国产在线观看91| 中文无码制服丝袜人妻av| 精品无码日韩一区二区三区不卡| 国产V亚洲V天堂无码久久久| 久久精品无码免费不卡| 亚洲天堂中文字幕| 丰满日韩放荡少妇无码视频| 精品无码人妻一区二区三区| 久久无码AV中文出轨人妻| 中文字幕一区二区三区精彩视频| 中文字幕亚洲男人的天堂网络| 亚洲乱码中文字幕综合234| 中文午夜乱理片无码| 中文有无人妻vs无码人妻激烈| 曰韩中文字幕在线中文字幕三级有码| 无码av中文一二三区| 久久亚洲av无码精品浪潮| 国产av永久无码天堂影院| 日韩乱码人妻无码中文字幕| 人妻一区二区三区无码精品一区| 无码视频在线观看| 亚洲国产精品无码AAA片| 亚洲中文久久精品无码ww16| 免费无码作爱视频| 中文字幕日韩精品在线| 欧美一级一区二区中文字幕 | 久久精品国产亚洲AV无码偷窥| 亚洲成A人片在线观看无码不卡 | 无码人妻AⅤ一区二区三区水密桃 无码欧精品亚洲日韩一区夜夜嗨 无码免费又爽又高潮喷水的视频 无码毛片一区二区三区中文字幕 无码毛片一区二区三区视频免费播放 | 国偷自产短视频中文版| 亚洲?v无码国产在丝袜线观看| 久久久精品无码专区不卡 | 中文字幕无码人妻AAA片| 欧美 亚洲 日韩 中文2019|